Blood and lymphatic system disorders – page 98

Study of Pioglitazone and Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia Patients After Stopping Treatment Attempts

Study of Pioglitazone and Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia Patients After Stopping Treatment Attempts

Study on Iberdomide for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem Cell Transplantation

Study on Iberdomide for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem Cell Transplantation

Study of Bexmarilimab Combined with Standard Treatment for Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Study of Avapritinib for Patients with Indolent Systemic Mastocytosis Not Adequately Managed by Standard Therapy

Study of Avapritinib for Patients with Indolent Systemic Mastocytosis Not Adequately Managed by Standard Therapy

Study of isatuximab and pegenzileukin combination treatment for patients with relapsed or refractory multiple myeloma who previously received anti-CD38 and anti-BCMA therapy

Study of isatuximab and pegenzileukin combination treatment for patients with relapsed or refractory multiple myeloma who previously received anti-CD38 and anti-BCMA therapy

Study Comparing Selinexor, Pomalidomide, and Dexamethasone with Elotuzumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Study Comparing Selinexor, Pomalidomide, and Dexamethasone with Elotuzumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Study of isatuximab, belantamab mafodotin and dexamethasone combination for patients with relapsed or refractory multiple myeloma

Study of isatuximab, belantamab mafodotin and dexamethasone combination for patients with relapsed or refractory multiple myeloma

Study of Isatuximab with Lenalidomide and Dexamethasone for Elderly Patients (70+) with Newly Diagnosed Multiple Myeloma

Study of Isatuximab with Lenalidomide and Dexamethasone for Elderly Patients (70+) with Newly Diagnosed Multiple Myeloma

Study of Venetoclax in Chronic Myeloid Leukemia Patients After Stopping Tyrosine Kinase Inhibitor Treatment

Study of Venetoclax in Chronic Myeloid Leukemia Patients After Stopping Tyrosine Kinase Inhibitor Treatment

Study on Early Response to Brentuximab Vedotin and Drug Combination for Advanced Hodgkin Lymphoma Patients

Study on Early Response to Brentuximab Vedotin and Drug Combination for Advanced Hodgkin Lymphoma Patients

Study on Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Study on Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Study of Belantamab Mafodotin, Carfilzomib, and Dexamethasone for Patients with Relapsed Multiple Myeloma Resistant to Lenalidomide

Study of Belantamab Mafodotin, Carfilzomib, and Dexamethasone for Patients with Relapsed Multiple Myeloma Resistant to Lenalidomide